Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Clinical trial NCT05687266 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05687266
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-29
- Primary completion
- 2027-11-01
- Enrollment
- 1350
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.